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Background. Substantial evidence exists for HLA and other host genetic factors being determinants of susceptibility or resistance to
infectious diseases. However, very little information is available on the role of host genetic factors in HIV-TB coinfection. Hence,
a longitudinal study was undertaken to investigate HLA associations in a cohort of HIV seropositive individuals with and without
TB in Bangalore, South India. Methods. A cohort of 238HIV seropositive subjects were typed for HLA-A, B, and DR by PCR-SSP
and followed up for 5years or till manifestation of Tuberculosis. HLA data of 682HIV Negative healthy renal donors was used as
control. Results. The ratio of males and females in HIV cohort was comparable (50.4% and 49.6%). But the incidence of TB was
markedly lower in females (12.6%,) than males (25.6%). Further, HLA-B∗57 frequency in HIV cohort was signiﬁcantly higher
among females without TB (21.6%, 19/88) than males (1.7%, 1/59); P = 0.0046; OR = 38. CD4 counts also were higher among
females in this cohort. Conclusion. This study suggests that HIV positive women with HLA-B∗57 have less occurrence of TB as
compared to males.
1.Introduction
India has the world’s highest number of Human immunode-
ﬁciencyvirus(HIV)infectionsforanycountryoutsideAfrica
with estimated 2.47million infections. The commonest
mode of transmission of infection is through heterosexual
contact and the majority of the HIV infections (89%) are
in the age group of 15–49 years. Karnataka is one of the
four states in Southern India which has a high prevalence
of HIV infection (0.81%), especially amongst ante-natal
mothers who are considered as low-risk group [1]. A recent
study from South India has indicated that HIV 1 clade C
accounts for over 90% of all HIV infections in the country
[2]. Amongst the 256 samples tested from South India, 253
wereidentiﬁedasHIV1cladeCusingasubtype-speciﬁcPCR
[2]. The predominant opportunistic infection noted among
AIDS patients in India is tuberculosis (TB) and it is the most
potent risk factor associated with disease progression. An
HIV positive person is six times (50 to 60% lifetime risk)
more likely to develop TB disease as compared to an HIV
negative person (10% lifetime risk) [3]. Notwithstanding
such a high risk of developing TB, it has been observed by2 Clinical and Developmental Immunology
us that there is a subset of HIV infected individuals who
do not develop TB over a number of years (unpublished
observations at Seva free clinic, an HIV care centre at
Bangalore). Taken together, this suggests that certain “innate
factors” could indeed inﬂuence the manifestation of TB in
HIV infected individuals. Interactions between HIV and the
innate immune system have recently caught the attention
of several researchers [4]. In particular, the importance of
diﬀerential Toll-Like Receptor 7 (TLR7) mediated signaling
leadingtoincreasedinterferon-αproductioninplasmacytoid
dendritic cells (pDCs) noted in HIV infected women as
compared to men thereby explaining how viral loads are
better controlled in women [5].
There is substantial epidemiological evidence that host
genetic factors such as Human Leukocyte Antigens (HLAs)
and closely linked genes of the Major Histocompatibility
Complex (MHC) as well as non-MHC factors such as
chemokine receptors are important determinants of suscep-
tibility or resistance to infectious diseases [6–8]. Human
Leukocyte Antigens are central to the recognition and pre-
sentation of pathogens to the immune system and therefore
are a fundamental part of the human immune system.
Several studies on HLA and disease association with HIV
have been reported in diﬀerent ethnic populations [6–8].
Little information is available on HIV infected individuals in
South India with special reference to the incidence of TB and
association with HLA. Therefore, this study was undertaken
in a cohort of HIV positive individuals to investigate the
association of HLA and TB.
2.MaterialsandMethods
2.1. Study Design. The study was prospective in design and
included 263 drug naive HIV seropositive individuals who
attended Seva Free Clinic (HIV care centre at Bangalore).
The study protocol was approved by the Institutional Ethical
Committees of Seva clinic and Bangalore Medical Services
Trust. Most patients visited the clinic with the onset of
symptoms and the duration of HIV infection was thus self-
reporting. HIV infection was conﬁrmed by demonstration
of anti-HIV antibodies in serum as per the National AIDS
Control Organization’s guidelines using rapid HIV tests. All
subjectsunderwentadetailedclinicalevaluationbythetreat-
ing physicians (Bhuthaiah Satish, Kadappa Shivappa Satish,
and Parthasarathy Satishchandra). TB was diagnosed in the
study subjects based on clinical examination and/or routine
laboratoryinvestigationssuchassputumsmearexamination,
X-ray chest, and haemogram. Sputum smear and/or culture
positivity was considered as conﬁrmatory evidence of TB,
whilst chest X-ray, raised erythrocyte sedimentation rates
and response to anti-TB treatment were considered highly
suggestive of TB. After obtaining informed consent, subjects
were recruited into the study and referred to the National
Institute of Mental Health and Neuro-Sciences (NIMHANS)
for CD4 enumeration. Those subjects who did not any con-
ﬁrmatoryand/orclinicalevidenceofTBwerefollowedupfor
a period of ﬁve years or till manifestation of TB, whichever
was earlier. During the follow-up period, 25/263 HIV
positive individuals were excluded from the study as their
CD4 counts declined below 200cells/μL and therefore had
to be initiated on antiretroviral therapy. No separate controls
wererecruitedforthisstudy,However,thesociodemographic
and HLA frequency distribution details available in a healthy
renal donor database with BMST, Bangalore, were used for
comparative analysis and interpretation of the data obtained
from study subjects. None of these donors were HIV positive
and showed any signs of active systemic tuberculosis upon
clinical examination. Their age, sociodemographic features,
and ethnic background (Dravidian race) were comparable to
those of the HIV infected group.
2.2. HLA Typing. HLA A, B, and DR typing was carried out
at Bangalore Medical Services Trust Immunophenotyping
laborator. HLA typing for the HIV positive cohort was
done by PCR-SSP low-to-intermediate resolution typing
employing commercial kits (Genovision, Biotest, and One
Lambda, USA) according to the manufacturer’s instructions.
We compared the frequency distribution of HLA antigens
among the HIV infected subjects with that of a 682 healthy
renal donor database on South Indians available at our
center. HLA typing for some of the renal donors was done
by serological methods employing commercial kits (One
Lambda, USA). The rest of the controls were typed by PCR-
SSP methods. Brieﬂy, 2mL of whole blood was collected
in ethylenediamine tetra acetic acid-( EDTA-) coated vaccu-
tainer tubes and DNA extracted using a commercial DNA
extractionkit(Qiagen,GmbH,Germany).ThepuriﬁedDNA
was added to the master mix containing Taq polymerase and
dNTP-buﬀer, dispensed into the 96-well Micro SSP DNA
Typing tray, which was precoated with primer pairs speciﬁc
for the diﬀerent HLA Class I and II, alleles, and ampliﬁed by
Polymerase Chain Reaction. The ampliﬁed DNA fragments
were separated using agarose gel electrophoresis and visu-
alized by staining with ethidium bromide and exposure to
UV light. Interpretation of the results was based on presence
or absence of a speciﬁc ampliﬁed DNA fragment. Results
were interpreted using speciﬁc interpretation work sheet and
speciﬁc software provided by the kit manufacturer. The HLA
typing was carried out for the following alleles: twenty two
H L AC l a s sIAl o c u sa n t i g e n s( 1 ,2 ,3 ,1 0 ,1 1 ,2 3 ,2 4 ,2 5 ,2 6 ,
29, 30, 31, 32, 33, 34, 36, 43, 66, 68, 69, 74, and 80), thirty six
HLA Class I B locus antigens (7, 8, 12, 13, 15, 16, 18, 21, 22,
27, 35, 37, 38, 39, 41, 42, 44, 45, 47, 48, 49, 50, 51, 52, 53, 55,
56, 57, 58, 60, 61, 62, 63, 71, 75, and 81), and eighteen HLA
Class II DR locus antigens (1, 3, 4, 7, 8, 9, 10, 11, 12, 13, 14,
15, 16, 17, and 18).
2.3. CD4 Counts. CD4 counts were enumerated at the WHO
accredited laboratory at the Department of Neurovirology,
NIMHANS, using a nonlysis method on a Fluorescent
Activated Cell Sort Count (FACSCount, Becton Dickenson,
USA). Brieﬂy, 50μL each of whole peripheral venous blood
was pipetted into a pair of reagent tubes containing the
CD4/CD3 and CD8/CD3 ﬂuorescent-labeled monoclonal
antibodies, respectively. The sample was vortexed for a few
seconds and incubated at room temperature for one hour.
Following the incubation period, 50μL of formalin ﬁxative
solution was added to each of the reagent tube pairs and theClinical and Developmental Immunology 3
counts were analyzed on the FACS count machine using the
specialized software provided by the manufacturer.
2.4. Statistical Analysis. The statistical analysis was done
using SPSS 15.0 and Epistat software. The tests used were
Chi-square test, Fisher’s exact probability test, and Student’s
t-test, wherever necessary Odds Ratios were computed. The
level of signiﬁcance was ﬁxed at 0.05.
3. Results
3.1. Socio-Demographic Proﬁle of Study Population. Amongst
the 238 subjects enrolled in this study, 120 (50.4%) were
males and 118 (49.6%) were females. Of these, 161 were
from lower socioeconomic strata, 46 from middle, and 1
from upper socioeconomic strata. The socioeconomic status
data for the rest (30 individuals) was not available. 74 of the
118 females gave their occupation as housewife. The age of
the HIV positive subjects ranged from 23 to 72 years with a
medianageof30years.Mostpatientsvisitedtheclinictoseek
medical intervention for signs and symptoms of illness. The
precise duration of HIV infection could not be determined
precisely as they were either referred from other health care
facilities or sought medical consultation voluntarily. The
duration of HIV infection was therefore estimated as at least
from the ﬁrst date of attendance at Seva clinic. This ranged
from 1 to 12 years and in 101/238 it ranged from 4 to 5 years
prior to recruitment in this study.
Amongst the 682 apparently healthy renal donor popula-
tions whose socio-demographic details were available in the
BMST database, it was observed that the age ranged from 21
to70yearswithamedianof39yearsandamale:femaleratio
of 1.21:1. All the renal donors were from South India and
from a similar ethnic origin as those study subjects.
3.2. Incidence of TB in HIV Positive Subjects. Table 1 depicts
the details of occurrence of TB in the study population.
Amongst the 238 subjects enrolled into this study 83 (34.9%)
were diagnosed to have TB (56 males and 27 females) at
the time of recruitment. Amongst the 83 subjects diagnosed
to have TB, 13 were positive for acid fast bacilli (AFB) on
sputum (n = 9) and CSF (n = 4) smear examination, 24
had typical ﬁndings of pulmonary TB on X-ray examination
(which included 4 with pleural eﬀusion), 11 were positive
for AFB on ﬁne needle aspiration cytology of lymph nodes,
3 had evidence of abdominal TB, and the remaining 32
showed excellent clinical response top anti-TB treatment
(resolution of abnormal X-ray chest ﬁndings or lymph
node enlargement). In the 155 HIV positive subjects who
had no evidence of TB at the time of recruitment, eight
developed TB during the ﬁve-year follow-up period (5 males
and 3 females). On the other hand, the gender distribution
amongst the 147 subjects who did not manifest TB at
recruitment or during the subsequent follow-up period
showed that women constituted 60% (88/147) while males
accountedfor40%(59/147).Overall,theincidenceofTBwas
markedly lower among female subjects (25.42%; 30/118) as
compared to male subjects (50.83%; 61/120).
Table 1: Occurrence of TB amongst HIV positive subjects.
HIV positive subjects
(n = 238)
Males
(n = 120)
Females
(n = 118)
No TB either at
recruitment or during
follow-up
59 (49.16%) 88 (74.57%)
TB positive individuals
in the study
(i) At recruitment 56 27
(ii) During follow-up 5 3
Total 61 30
3.3. Comparison of HLA Frequencies among the HIV Positive
Cohort and Healthy Renal Donors. T h ef o l l o w i n gC l a s sIa n d
Class II, HLA Antigens were identiﬁed in the samples in our
study: HLA A: 1, 2, 3, 10, 11, 23, 24, 26, 29, 30, 31, 32, 33, 34,
36, 68, and 74; HLA B: 7, 8, 12, 13, 15, 18, 21, 27, 35, 37, 38,
39, 41, 42, 44, 47, 48, 49, 50, 51, 52, 53, 55, 56, 57, 58, 60, 61,
62, 63, 71, 75, and 81; HLA DR:1, 3, 4, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, and 18.
Tables 2(a), 2(b), and 2(c) depict the frequency distribu-
tion of the HLA A, B, and DR alleles, respectively, among
the healthy renal donors and the HIV positive subjects.
Interestingly, HLA-A∗2 (31%), HLA-B∗35 (26%), and HLA-
DRB1∗15 (20%) were found to be the most frequently
occurring alleles in both HIV positive cohort and the
healthy renal donors. Amongst the healthy renal donors,
the incidence of individual HLA antigens did not show
any signiﬁcant diﬀerences between males and females. With
respect to HIV positive cohort the following observations
were made: (i) frequency of HLA-A∗2 was higher among
TB positive women (Table 2(a)), (ii) frequency of HLA-
B∗35 was lower among TB negative women, (iii) HLA-
B∗52 and HLA-B∗62 alleles were not detected among TB
positive women, (iv) frequency of HLA-B∗61 was higher
among TB positive women (Table 2(b)), (v) HLA-DRB1∗4
and HLA-DRB1∗15 frequencies were higher among HIV
positive subjects as compared to the healthy renal donors,
and (vi) frequency of HLA-DRB1∗8 was higher among TB
positivemen(Table 2(c)).However,noneofthesediﬀerences
were statistically signiﬁcant. On the other hand, there was
a signiﬁcantly diﬀerent distribution of HLA-B∗57 among
HIV positive TB negative female subjects as compared to
HIV positive males as well as male and female healthy renal
donors (controls).
3.4. Frequency Distribution of HLA-B∗57 (Table 2(b)).
Among the 682 healthy, HIV negative, renal donors, the
frequency distribution of HLA-B∗57 in the males and
females was comparable (9.48% and 12.77%, resp.). The
incidence of HLA-B∗57 among HIV Positive males was low,
being only 4.2% (n = 5), but the diﬀerence as compared to
the renal donor data was not statistically signiﬁcant. Though
the proportion of HIV positive females with HLA-B∗57 was
more(17.8%,n = 21)ascomparedto12.77%amonghealthy
female renal donors, it did not reach statistical signiﬁcance
(Chi-square =1.50; df = 1 P>0.05). The frequency of HLA-
B∗57 amongst HIV positive males with TB (6.55%; 4/61)4 Clinical and Developmental Immunology
Table 2: (a) Frequency distribution of HLA A alleles among HIV positive subjects with and without TB and among healthy renal donors
(control sample). (b) Frequency distribution of HLA B alleles among HIV positive subjects with and without TB and among healthy renal
donors(controlsample).(c)FrequencydistributionofHLADRallelesamongHIVpositivesubjectswithandwithoutTBandamonghealthy
renal donors (control sample).
(a)
HLA A
HIV positive females HIV positive males Healthy renal donors
TB neg. F TB pos. F TB neg. M TB pos. M Females Males
n = 88 n = 30 n = 59 n = 61 n = 376 n = 306
1 29 (33.0%) 9 (30.0%) 14 (23.7%) 15 (24.6%) 84 (22.3%) 65 (21.2%)
2 27 (30.7%) 12 (40.0%) 20 (33.9%) 19 (31.1%) 115 (30.6%) 95 (31.0%)
3 10 (11.4%) 3 (10.0%) 10 (16.9%) 7 (11.5%) 54 (14.4%) 32 (10.5%)
10 1 (1.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0%) 0 (0%)
11 23 (26.1%) 7 (23.3%) 13 (22.0%) 17 (27.9%) 96 (25.5%) 82 (26.8%)
23 1 (1.1%) 0 (0.0%) 0 (0.0%) 1 (1.6%) 2 (0.5%) 10 (3.3%)
24 20 (22.7%) 8 (26.7%) 16 (27.1%) 20 (32.8%) 97 (25.8%) 79 (25.8%)
25 0 (0.0%) 0 (0.0%) 0 (0%) 0 (0%) 1 (0.3%) 1 (0.3%)
26 5 (5.7%) 2 (6.7%) 3 (5.1%) 5 (8.2%) 23 (6.1%) 23 (7.5%)
29 2 (2.3%) 4 (13.3%) 3 (5.1%) 3 (4.9%) 17 (4.5%) 10 (3.3%)
30 1 (1.1%) 0 (0.0%) 1 (1.7%) 2 (3.3%) 10 (2.7%) 14 (4.6%)
31 8 (9.1%) 1 (3.3%) 6 (10.2%) 1 (1.6%) 28 (7.4%) 28 (9.2%)
32 4 (4.5%) 1 (3.3%) 4 (6.8%) 3 (4.9%) 17 (4.5%) 10 (3.3%)
33 15 (17.0%) 5 (16.7%) 11 (18.6%) 11 (18.0%) 93 (24.7%) 72 (23.5%)
34 0 (0.0%) 0 (0.0%) 1 (1.7%) 0 (0.0%) 0 (0%) 1 (0.3%)
36 0 (0.0%) 0 (0.0%) 1 (1.7%) 0 (0.0%) 2 (0.5%) 5 (1.6%)
43 0 (0.0%) 0 (0.0%) 0 (0%) 0 (0%) 1 (0.3%) 0 (0%)
66 0 (0.0%) 0 (0.0%) 0 (0%) 0 (0%) 0 (0%) 2 (0.7%)
68 13 (14.8%) 6 (20.0%) 7 (11.9%) 9 (14.8%) 51 (13.6%) 32 (10.5%)
74 0 (0.0%) 0 (0.0%) 0 (0%) 0 (0%) 2 (0.5%) 5 (1.6%)
80 0 (0.0%) 0 (0.0%) 0 (0%) 0 (0%) 1 (0.3%) 0 (0%)
(b)
HIV positive females HIV positive males Healthy renal donors
HLA B TB neg. F TB pos. F TB neg. M TB pos. M Females Males
n = 88 n = 30 n = 59 n = 61 n = 376 n = 306
7 18 (20.5%) 5 (16.7%) 13 (22.0%) 10 (16.4%) 71 (18.9%) 48 (15.7%)
8 4 (4.5%) 4 (13.3%) 2 (3.4%) 4 (6.6%) 5 (1.3%) 13 (4.2%)
13 2 (2.3%) 1 (3.3%) 1 (1.7%) 4 (6.6%) 23 (6.1%) 28 (9.2%)
15 2 (2.3%) 1 (3.3%) 2 (3.4%) 0 (0.0%) 7 (1.9%) 13 (4.2%)
18 0 (0.0%) 1 (3.3%) 2 (3.4%) 4 (6.6%) 12 (3.2%) 12 (3.9%)
21 4 (4.5%) 2 (6.7%) 3 (5.1%) 2 (3.3%) 0 (0.0%) 4 (1.3%)
27 5 (5.7%) 1 (3.3%) 2 (3.4%) 1 (1.6%) 9 (2.4%) 12 (3.9%)
35 15 (17.0%) 8 (26.7%) 18 (30.5%) 20 (32.8%) 104 (27.7%) 75 (24.5%)
37 9 (10.2%) 3 (10.0%) 4 (6.8%) 8 (13.1%) 26 (6.9%) 26 (8.5%)
38 0 (0.0%) 0 (0.0%) 2 (3.4%) 3 (4.9%) 10 (2.7%) 8 (2.6%)
39 0 (0.0%) 1 (3.3%) 0 (0.0)% 1 (1.6%) 3 (0.8%) 8 (2.6%)
41 0 (0.0%) 0 (0.0%) 0 (0.0)% 1 (1.6%) 1 (0.3%) 4 (1.3%)
42 1 (1.1%) 0 (0.0%) 0 (0.0)% 0 (0.0%) 1 (0.3%) 3 (1.0%)
44 7 (8.0%) 1 (3.3%) 11 (18.6)% 8 (13.1%) 51 (13.6%) 51 (16.7%)
45 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.5%) 2 (0.7%)
47 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.7%)
48 0 (0.0%) 0 (0.0%) 2 (3.4%) 0 (0.0%) 6 (1.6%) 3 (1.0%)
49 1 (1.1%) 1 (3.3%) 0 (0.0)% 1 (1.6%) 7 (1.9%) 3 (1.0%)
50 2 (2.3%) 0 (0.0%) 2 (3.4%) 1 (1.6%) 9 (2.4%) 7 (2.3%)
51 18 (20.5%) 8 (26.7%) 16 (27.1%) 14 (23.0%) 59 (15.7%) 34 (11.1%)
52 15 (17.0%) 0 (0.0%) 6 (10.2%) 6 (9.8%) 37 (9.8%) 36 (11.8%)Clinical and Developmental Immunology 5
(b) Continued.
HIV positive females HIV positive males Healthy renal donors
HLA B TB neg. F TB pos. F TB neg. M TB pos. M Females Males
n = 88 n = 30 n = 59 n = 61 n = 376 n = 306
53 0 (0.0%) 1 (3.3%) 1 (1.7%) 0 (0.0%) 9 (2.4%) 10 (3.3%)
55 2 (2.3%) 1 (3.3%) 1 (1.7%) 2 (3.3%) 6 (1.6%) 5 (1.6%)
56 3 (3.4%) 0 (0.0%) 0 (0.0)% 0 (0.0%) 7 (1.9%) 3 (1.0%)
57 19 (21.6%) 2 (6.7%) 1 (1.7%) 4 (6.6%) 48 (12.8%) 29 (9.5%)
58 4 (4.5%) 1 (3.3%) 3 (5.1%) 3 (4.9%) 33 (8.8%) 25 (8.2%)
40 23 (26.1%) 10 (33.3%) 8 (13.6%) 12 (19.7%) 13 (3.5%) 13 (4.2%)
60 6 (6.8%) 1 (3.3%) 3 (5.1%) 1 (1.6%) 26 (6.9%) 14 (4.6%)
61 17 (19.3%) 9 (30.0%) 5 (8.5%) 11 (18.0%) 51 (13.6%) 38 (12.4%)
62 8 (9.1%) 0 (0.0%) 4 (6.8%) 3 (4.9%) 18 (4.8%) 15 (4.9%)
63 0 (0.0%) 0 (0.0%) 1 (1.7%) 0 (0.0%) 2 (0.5%) 4 (1.3%)
65 0 (0.0%) 0 (0.0%) 0 (0.0)% 0 (0.0%) 1 (0.3%) 0 (0.0%)
70 0 (0.0%) 0 (0.0%) 0 (0.0)% 0 (0.0%) 12 (3.2%) 7 (2.3%)
71 1 (1.1%) 0 (0.0%) 1 (1.7%) 1 (1.6%) 4 (1.1%) 11 (3.6%)
75 2 (2.3%) 1 (3.3%) 1 (1.7%) 3 (4.9%) 8 (2.1%) 6 (2.0%)
77 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%)
78 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%)
81 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (0.8%) 4 (1.3%)
(c)
HIV positive females HIV positive males Healthy renal donors
HLA DR TB neg. F TB pos. F TB neg. M TB pos. M Females Males
n = 88 n = 30 n = 59 n = 61 n = 376 n = 306
1 5 (5.7%) 3 (10.0%) 6 (10.2%) 5 (8.2%) 17 (4.52%) 19 (6.21%)
3 0 (0.0%) 0 (0.0%) 1 (1.7%) 0 (0.00%) 9 (2.39%) 9 (2.94%)
4 20 (22.7%) 5 (16.7%) 17 (28.8%) 13 (21.3%) 39 (10.37%) 40 (13.07%)
7 22 (25.0%) 5 (16.7%) 8 (13.6%) 11 (18.0%) 72 (19.15%) 44 (14.38%)
8 3 (3.4%) 0 (0.0%) 1 (1.7%) 7 (11.5%) 3 (0.80%) 8 (2.61%)
9 0 (0.0%) 0 (0.0%) 1 (1.7%) 1 (1.6%) 0 (0.00%) 5 (1.63%)
10 11 (12.5%) 3 (10.0%) 9 (15.3%) 11 (18.0%) 36 (9.57%) 24 (7.84%)
11 9 (10.2%) 3 (10.0%) 6 (10.2%) 9 (14.8%) 20 (5.32%) 25 (8.17%)
12 3 (3.4%) 1 (3.3%) 4 (6.8%) 2 (3.3%) 14 (3.72%) 17 (5.56%)
13 13 (14.8%) 6 (20.0%) 12 (20.3%) 10 (16.4%) 47 (12.50%) 22 (7.19%)
14 20 (22.7%) 4 (13.3%) 11 (18.6%) 10 (16.4%) 34 (9.04%) 23 (7.52%)
15 47 (53.4%) 17 (56.7%) 26 (44.1%) 26 (42.6%) 105 (27.93%) 98 (32.03%)
16 4 (4.5%) 2 (6.7%) 1 (1.7%) 0 (0.00%) 4 (1.06%) 5 (1.63%)
17 3 (3.4%) 1 (3.3%) 3 (5.1%) 7 (11.5%) 9 (2.39%) 10 (3.27%)
18 0 (0.0%) 1 (3.3%) 0 (0.0%) 0 (0.00%) 0 (0.00%) 3 (0.98%)
∗Using Chi-square test, the signiﬁcance of frequency distribution of various HLA alleles was compared between males and females of HIV subjects with and
with out TB as well as in healthy renal donors. The only signiﬁcant observation noted was lower occurrence of TB in HLAB57 positive HIV infected women
(P = 0.0046).
and females with TB (6.66%; 2/30) showed no statistical
diﬀerence. However, the frequency distribution of HLA-
B∗57 in HIV positive, TB Negative females was 21.59%,
(19/88), signiﬁcantly higher (P = 0.0046 with an Odds
Ratio of 3.80) than that in HIV positive TB negative males
(1.7%; 1/59). Thus the frequency distribution of HLA-B∗57
antigen among the HIV population was proportionately
more amongst women who did not develop TB as compared
to men who did not develop TB. In other words, the relative
risk (RR) of HIV positive HLA-B∗57 females developing TB
was signiﬁcantly lower (0.26) as compared to males (4.07).
When calculated with Haldane-modiﬁed Woolf’s formula
the RR of HIV positive HLA-B∗57 females developing TB
was signiﬁcantly lower (0.31) as compared to males (3.87).
3.5. CD4 Counts. The CD4 counts were estimated in 227
subjects (115 females and 112 males) and ranged from 2 to
1155/μL. In 11 HIV positive subjects (3 females and 8 males)6 Clinical and Developmental Immunology
CD4 counts were not estimated. Overall females had higher
CD4 counts than males with 26 females and 14 males having
CD4 counts >500/μL, 66 females and 57 males from 200 to
500/μL, and 23 females and 41males <200/μL. HIV positive
individualswithTBhadlowerCD4countsthanHIVpositive
individuals without TB.
3.6. CD4 Counts in Subjects with HLA-B∗57. Amongst the
TB positive HLA-B∗57 subjects, CD4 counts in 2 females
were <200/μL while in 3 out of 4 males they were from 201
to 500/μLa n d>501/μL in 1out of 4 males. Amongst the
TB negative HLA-B∗57 subjects, CD4 counts in 1 out of 19
females were less than 200/μL, from 201 to 500/μLi n7o u t
of 19 females, and >501μL in 11/19 females. The lonly HLA-
B∗57 male who was TB negative had a CD4 count of 374/μL.
Overall CD4 counts in the HLA-B∗57 females were higher
than those in HLA-B∗57 males.
4. Discussion
Several studies in diﬀerent ethnic populations have noted
associations between HLA alleles and HIV infection disease
progression to AIDS. These studies have demonstrated that
the host immune response to HIV infection is inﬂuenced
by the MHC repertoire of the individual. While some HLA
alleles notably HLA-B57 and HLA-B27 were associated with
favourable outcomes, others including HLA-B35 and HLA-
B22 were associated with unfavourable outcomes [6–9].
Of the many alleles implicated, HLA-B57 has presented
a remarkably consistent protective eﬀect in HIV positive
individuals in various ethnic populations of the world
resulting in low viremia, high CD4 counts, and a Long-
Term Nonprogressor (LTNP) state [10, 11]. Both innate and
adaptiveprotectiveimmunemechanismsplayapartinLong-
Term Nonprogressors, mediated by Cytotoxic T Lymphocyte
(CTL) and Natural Killer (NK) cell responses in the context
of HLA alleles. HLA B∗57-restricted HIV-1-speciﬁc CTL
responses and protective Killer Immunoglobulin-like Recep-
tor (KIR) alleles in combination with the HLA-B∗57 alleles
have been demonstrated in LTNPs [12–14]. Other related
HLA genes have been shown to contribute to the protective
eﬀect mediated by sharing of HLA-B57/B58-restricted CTL
epitopes [15, 16]. Several studies have noted that there is
signiﬁcant correlation between HIV-1-speciﬁc CD8 T-cell
proliferation and HIV replicative capacity, resulting in low
viral load and therefore slower progression [17–19]. A study
in France in an HIV-1 cohort of slow and rapid progressors
found among others an association of HLA DR11 with rapid
progression but only among women [7]. While some studies
have noted a slower disease progression but a higher rate of
death in HIV positive women than in men [20], others have
noted a faster disease progression to AIDS [21].
Several studies have also investigated the possible role
of HLA alleles in the incidence and progression of TB.
For instance, some studies from India and other countries
have reported diﬀerent HLA alleles that are associated with
incidence and progression of TB [6, 22–24], particularly
the association of DRB∗1501 with advanced disease and
failure to respond to drug therapy. Other studies from
India and elsewhere have noted a lower incidence of TB
disease among adult females than in adult males, compared
to children and adolescents. Smoking has been implicated
in the increased incidence of TB among men and gender
inequalities and socioeconomic factors for the diﬀerences
in the epidemiology of TB, HIV, and other diseases in men
and women [25–29]. Nevertheless biological factors also
have been seen to be associated with the gender diﬀerences
of these diseases. All these studies have contributed to the
better understanding of the possible role of HLA genes
in HIV disease progression and/or occurrence of TB in
the population. However none of them have addressed
the important aspect of HIV-TB coinfections. Since TB is
one of the common opportunistic infections encountered
in HIV infected subjects, studying the possible role of
host genetic elements involved in the occurrence of TB is
critical. Therefore, in this study we undertook HLA typing
in a cohort of HIV infected individuals with and without
TB to investigate whether host genetics would explain the
paradoxical clinical observation of absence of TB amongst
HIV infected subjects in South India.
In our HIV positive study population, the incidence of
TB among females was signiﬁcantly lower than in males.
Although there was a higher incidence of TB among the men
who reported tobacco use (23/45 TB positive males and data
related to smoking was unavailable in the remaining 16 TB
positive males), it was not statistically signiﬁcant. Therefore,
smoking alone cannot explain the higher incidence of TB
among the men in our study. The present study on HLA
association in an Indian HIV positive cohort conﬁrms the
LTNP protective eﬀect of HLA-B57, which has been reported
in various parts of the world [9–14]. The proportion of
HIV positive females with HLA-B∗57 who did not develop
TB in our study was signiﬁcantly high (P = .0046).
This observation assumes greater signiﬁcance given that
the male-to-female ratio in the HIV positive cohort was
comparable (50.4% males to 49.6% females). The females
with HLA-B∗57 also possessed higher CD4 counts. It is
possible that this may be indicative of HLA-B∗57 having a
protective eﬀect in females with HIV and slower progression
of HIV disease. Yet, this protective inﬂuence of HLA-
B∗57 was not clearly apparent in the male HIV positive
individuals. Hormonal inﬂuence on noninfectious diseases
like cardiovascular disorders is known. But some studies on
HIV disease progression, including our own, are suggestive
of hormone-mediated adaptive immune responses in the
control of infectious diseases [9]. Alternatively, the higher
CD4 counts in females may be because of the lower rates
of TB in HIV positive women noted in this study, especially
because the duration of HIV infection is unknown in our
subjects.
Mutations in HIV-1 due to founder eﬀects and HLA
class I-mediated immune mutations contribute to viral gene
diversity, which in turn may impact the HLA diversity at
the population level [30–32]. The HLA A1-B57 haplotype
is of greater frequency in the Indian population suggestive
of a possible survival advantage [33]. HLA-B∗57 is present
in a signiﬁcant proportion of the population in India and
in our control sample it was 11.1% (data not presented).Clinical and Developmental Immunology 7
The HIV pandemic in India is still in a state of expansion.
In conclusion, this initial study highlights the association of
gender, presence of HLA-B∗57, and slow progression of HIV
infection. However, larger prospective studies are needed to
clearly deﬁne the role played by HLA mediated and other
non-HLA immune mechanisms for susceptibility (risk) or
protection which can be used for immunogenetic proﬁling,
risk assessment, therapeutic decisions, and for future vaccine
development and treatment.
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